Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ENLV | US
-0.02
-2.01%
Healthcare
Biotechnology
30/06/2024
24/04/2026
0.89
0.90
0.93
0.88
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona Israel.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
81.7%1 month
103.8%3 months
81.8%6 months
80.6%-
-
1.22
0.03
0.03
-1.49
-
-
-17.89M
19.02M
19.02M
-
-
-
-
-61.17
0.70
0.52
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.23
Range1M
0.58
Range3M
0.58
Rel. volume
0.23
Price X volume
228.12K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| RenovoRx Inc. Common Stock | RNXT | Biotechnology | 0.8566 | 20.55M | -4.82% | n/a | 0.00% |
| Aligos Therapeutics Inc | ALGS | Biotechnology | 6.4 | 20.46M | 4.40% | n/a | 14.63% |
| Inhibikase Therapeutics Inc. | IKT | Biotechnology | 1.88 | 18.75M | -2.59% | n/a | 3.49% |
| PLUR | PLUR | Biotechnology | 3.345 | 18.30M | -2.76% | n/a | 30845.83% |
| DOMH | DOMH | Biotechnology | 2.89 | 18.14M | 0.00% | n/a | 7.66% |
| DarT Bioscience Inc | DARE | Biotechnology | 2.11 | 18.03M | -0.47% | 0.12 | 218.34% |
| Can-Fite BioPharma Ltd | CANF | Biotechnology | 2.91 | 17.74M | 0.00% | n/a | 0.00% |
| ICU | ICU | Biotechnology | 4.13 | 17.31M | -2.59% | n/a | -45.50% |
| Cingulate Inc. Common Stock | CING | Biotechnology | 5.47 | 16.65M | -2.67% | n/a | 10.72% |
| HCW Biologics Inc. Common Stock | HCWB | Biotechnology | 0.3756 | 16.39M | -8.23% | n/a | -159.13% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.49 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.22 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 81.78 | 72.80 | Par |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 19.02M | 3.66B | Emerging |